Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 43

    1.

    Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

    Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

    N Engl J Med. 2012 Jan 26;366(4):310-20.

    PMID:
    22276821
    [PubMed - indexed for MEDLINE]
    2.

    Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

    von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

    N Engl J Med. 2012 Jan 26;366(4):299-309.

    PMID:
    22276820
    [PubMed - indexed for MEDLINE]
    3.

    Fighting fire with fire: rekindling the bevacizumab debate.

    Montero AJ, Vogel C.

    N Engl J Med. 2012 Jan 26;366(4):374-5. No abstract available.

    PMID:
    22276827
    [PubMed - indexed for MEDLINE]
    4.

    Breast-cancer screening.

    Fitzgerald SP.

    N Engl J Med. 2012 Jan 12;366(2):191; author reply 191-2. No abstract available.

    PMID:
    22236240
    [PubMed - indexed for MEDLINE]
    5.

    Breast-cancer screening.

    Newman DH.

    N Engl J Med. 2012 Jan 12;366(2):191; author reply 191-2. No abstract available.

    PMID:
    22236239
    [PubMed - indexed for MEDLINE]
    6.

    Breast-cancer screening.

    Mattheis J.

    N Engl J Med. 2012 Jan 12;366(2):190-1; author reply 191-2. No abstract available.

    PMID:
    22236238
    [PubMed - indexed for MEDLINE]
    7.

    Error occurred: cannot get document summary

    PMID:
    22236237

    8.

    Breast-cancer adjuvant therapy with zoledronic acid.

    van der Vliet HJ, Verheul HM.

    N Engl J Med. 2012 Jan 12;366(2):188-9; author reply 189. No abstract available.

    PMID:
    22236236
    [PubMed - indexed for MEDLINE]
    9.

    Error occurred: cannot get document summary

    PMID:
    22236235

    10.

    HER2 therapy--an abundance of riches.

    Gradishar WJ.

    N Engl J Med. 2012 Jan 12;366(2):176-8. Epub 2011 Dec 7. No abstract available.

    PMID:
    22149874
    [PubMed - indexed for MEDLINE]
    11.

    Clinical problem-solving. Breathless.

    Gavin MC, Morse D, Partridge AH, Levy BD, Loscalzo J.

    N Engl J Med. 2012 Jan 5;366(1):75-81. No abstract available.

    PMID:
    22216845
    [PubMed - indexed for MEDLINE]
    12.

    Interactive medical case. Breathless.

    Ross JJ, Vaidya A, Gavin MC, Morse D, Partridge AH.

    N Engl J Med. 2011 Dec 22;365(25):e47. No abstract available.

    PMID:
    22188008
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

    Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.

    N Engl J Med. 2012 Feb 9;366(6):520-9. Epub 2011 Dec 7.

    PMID:
    22149876
    [PubMed - indexed for MEDLINE]
    14.

    Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

    Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.

    N Engl J Med. 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7.

    PMID:
    22149875
    [PubMed - indexed for MEDLINE]
    15.

    Breast-cancer adjuvant therapy with zoledronic acid.

    Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators.

    N Engl J Med. 2011 Oct 13;365(15):1396-405. Epub 2011 Sep 25.

    PMID:
    21995387
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    The avastin story.

    Sekeres MA.

    N Engl J Med. 2011 Oct 13;365(15):1454-5. No abstract available.

    PMID:
    21995408
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Steady progress against HER2-positive breast cancer.

    Hayes DF.

    N Engl J Med. 2011 Oct 6;365(14):1336-8. No abstract available.

    PMID:
    21991956
    [PubMed - indexed for MEDLINE]
    18.

    Adjuvant trastuzumab in HER2-positive breast cancer.

    Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

    N Engl J Med. 2011 Oct 6;365(14):1273-83.

    PMID:
    21991949
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Adverse health outcomes in women exposed in utero to diethylstilbestrol.

    Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T, Hartge P, Hatch EE, Herbst AL, Karlan BY, Kaufman R, Noller KL, Palmer JR, Robboy SJ, Saal RC, Strohsnitter W, Titus-Ernstoff L, Troisi R.

    N Engl J Med. 2011 Oct 6;365(14):1304-14.

    PMID:
    21991952
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Case 17-2011: a woman with a mass in the breast and overlying skin changes.

    Saloustros E, Mavroudis D.

    N Engl J Med. 2011 Sep 29;365(13):1259-60; author reply 1260. No abstract available.

    PMID:
    21991911
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk